Myoblast Transfer in the Treatment of Duchenne's Muscular Dystrophy
Jerry R. Mendell(Nationwide Children's Hospital), Arthur H.M. Burghes(The Ohio State University Wexner Medical Center), L. Signore(The Ohio State University), Glen E. Morris, Patricia McAndrew(The Ohio State University), Robert Rice(The Ohio State University), Anthony A. Amato(Brigham and Women's Hospital), Laura E. Lantry(The Ohio State University), John T. Kissel(The Ohio State University), Ralph E. Stephens(The Ohio State University), Thomas W. Prior(Goethe University Frankfurt), Sandra Benson(The Ohio State University), Zarife Sahenk(The Ohio State University), Wendy King(The Ohio State University), Haikady N. Nagaraja(The Ohio State University)
Cited by 522
Related Papers
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Evidence‐based path to newborn screening for duchenne muscular dystrophy
|Annals of Neurology|2012|816
Eteplirsen for the treatment of Duchenne muscular dystrophy
|Annals of Neurology|2013|793
The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle
|Nature|1988|659
Dystrophin Immunity in Duchenne's Muscular Dystrophy
|New England Journal of Medicine|2010|655